Lung Disease
Study results from National Cancer Center Hospital East broaden understanding of lung disease
Published in Drug Week, September 24th, 2010
Data detailed in 'Severe interstitial lung disease associated with amrubicin treatment' have been presented. According to recent research from Kashiwa, Japan, "Amrubicin is a novel anthracycline agent that is well known to exert significant activity against small cell lung cancer (SCLC), but the adverse pulmonary effects of amrubicin are less well known. We investigated the incidence of acute interstitial lung disease (ILD) in SCLC patients who had been treated with amrubicin."
"Medical records were used to retrospectively investigate a total of 100 cases of SCLC patients treated with single-agent amrubicin therapy at the National Cancer Center Hospital East between...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2010-09-24)
More Articles from Drug Week
- Albany Molecular Research, Inc.
AMRI CFO to Present at the Rodman & Renshaw Annual Global Investment Conference - Drug Abuse
City of Henderson to Present 'Operation Medicine Cabinet' in Conjunction with National Drug Take Back Day - Doxorubicin Therapy
Data from National Laboratory of Biomacromolecules advance knowledge in doxorubicin therapy - Angiology
Data from University of Glasgow provide new insights into angiology - Neuroscience
Data from University of Michigan provide new insights into neuroscience - Antibiotics
Data on antibiotics described by R. Lopez-Roldan et al - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
